Good
Mostly Aligned
Patient Risk:
Low
Summary
Overall alignment with the label is generally accurate for mechanism, lipid-lowering effects, and major cardiovascular-indication rationale, with partial support for grapefruit interactions and several safety-related omissions noted.
Category Scores
Accurate Statements
Lipitor is a statin medication that belongs to the HMG-CoA reductase inhibitor class.
12.1
Lipitor works by blocking the production of cholesterol in the liver.
12.1
Lipitor lowers low-density lipoprotein (LDL) cholesterol in the blood.
12.1
By reducing LDL cholesterol, Lipitor helps to lower the risk of heart disease, heart attacks, and strokes.
1.1
Grapefruit juice contains a compound called furanocoumarin, which can inhibit the enzyme CYP3A4 in the small intestine.
7.2 (partially supported)
This enzyme is responsible for metabolizing atorvastatin, the active ingredient in Lipitor.
12.3
When grapefruit juice is consumed, it can slow down the metabolism of atorvastatin, leading to increased levels of the medication in the bloodstream.
7.2, 12.3
Grapefruit juice can increase the risk of muscle damage with Lipitor, including muscle pain, weakness, and fatigue.
5.1, 7
Grapefruit juice may interact with other medications, such as blood thinners, diabetes medications, and certain antibiotics.
7, 7.2
Unsupported Statements
Grapefruit juice may increase the risk of liver damage with Lipitor, including elevated liver enzymes and liver failure.
Label discusses hepatic monitoring and hepatotoxicity risk for statins in general, but does not attribute grapefruit-specific liver injury to grapefruit-atorvastatin interaction in the cited sections.
Lipitor label states that patients should avoid consuming grapefruit juice or eating grapefruit while taking Lipitor.
Label sections cited do not consistently contain an explicit instruction to avoid grapefruit entirely; wording varies by label edition.
There is no specific dosage limit for grapefruit juice; the concern lies in the frequency and quantity of grapefruit juice consumption when taking Lipitor.
Label discusses interaction potential but does not provide a numeric grapefruit-juice dosage limit.
Contradictions
Important Omissions
Pregnancy risk and contraindication details for use in pregnancy
Importance:
Critical
Pediatric safety/use considerations
Importance:
Moderate
Boxed warning status (if applicable) for atorvastatin
Importance:
High
Dosing and administration specifics, including starting dose, titration, max dose, and hepatic impairment adjustments
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Many interactions are manageable with monitoring; however, myopathy and hepatic risk exist, especially with interacting drugs or high-dose therapy. Grapefruit interaction can increase atorvastatin exposure.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Clarify grapefruit-related guidance and ensure explicit, consistent statements about grapefruit interactions across label editions; address safety omissions (pregnancy, pediatric use, dosing specifics).
Suggested Improvement
Update or harmonize grapefruit interaction wording; explicitly note pregnancy and pediatric considerations; include concrete dosing/titration guidance and confirm boxed warning status if applicable.